6.

6.

, ,
, ,

262

(DA), (NE)

.

( )
.

, ( )
( ).

.

, nitrogen ohne
radical (. ).
- 1884

Dr George Oliver, Harrogate,

,
,
.

,
, ,
,

, Oliver
. ,
Edward Schfer
,
, .
Schfer Oliver,
. Oliver

. Schfer
, Oliver
,

, .

Sir Edward Albert Schfer

(1850 -1935)

.
.
. ,

: ,

,
.

:
~80%

() ~20%
()
,
.
, -- (fright-fight-flight),
.40
, ,

.
,

263

264

George Oliver Edward Schfer

Napoleon Cybulski Szymonowicz .
A - 1901

4-[1--2()]-1,2-, , .
;
.
John Jacob Abel, ,
University of Michigan Ann Arbor Johns Hopkins Medical School
Baltimore, , .
,
,
, ,
. C17H15NO4.
Jokichi Takamine,
Parke Davis Company (Detroit, Michingan)
Abel 1899 1900. Abel
, Takamine,
,
, ,
Adrenalin ( e).
Takamine ,
. O T.B. Aldrich, Parke Davis
Company, Takamine C9H13NO3.

John Jacob Abel

(1857-1938)

Jokichi Takamine
(1854-1922)

Parke Davis Company

, 1975,
. Abel

epinephrin ( e)
, .

: ,

Journal of Biological Chemistry.
,
, Abel 10 C 10H13NO3.


, 9 .
.
Dakin Stolz
1904/5.
: - 1904

1904, Friedrich
Stolz (Farbwerke Hochst) Henry Drysdale Dakin (University of Leeds),
.

Friedrich Stolz
(1860 -1936)

Henry Drysdale Dakin

(1880 -1952)

265

266

1904, John Newport Langley

, Thomas Renton Elliott
Cambridge, 4 Journal of Physiology


. 1/
,
, . 2/
. 3/

.
John Newport Langley
(1852 1925)

1904 Otto Loewi , vagusstoff

,

: ,

acceleransstoff.

.

,
,

.
1936
. ,
,
, .
1910, Henry Dale
,
Otto Loewi (1873 1961)
,
Nobel 1936

. ,

. ,
,
, 1940.
- fight or flight

Walter Bradford Cannon,

Harvard Medical School ,

. Cannon
, .
Cannon fight or flight.
,
, ,
,
.
1919,
Walter Bradford
, -
Cannon
.
(1871 1945)
1939, ()
: sympathin E
(excitatory) and sympathin I (inhibitory).
,
.
:
, .
,
,

.

.
(. ,

267

268

),
, . ,
, ,
( ).
,
,
, ,
-,
, o .

. 50
.
,

.
Parkinson, L-DOPA

.
DA 1939

1939,
Peter Holtz (19021970)
dopa decarboxylase,
CO2 L-Dopa.

Peter Holtz
(19021970)

6.24

1949, Edith Blbring ,

. 1962, Julius Axelrod Bethesda,
Maryland phenylethanolamine N-methyltransferase,
.
- 1946

Holtz Blaschko .
. 1946, Ulf von Euler

: ,

Karolinska Institutet Stockholm, substance P

, Nature :
1/
,
2/
3/ Cannon, the physiological
transmitter of adrenergic nerve action in mammals.

, .
- 1948

Ulf von Euler

(1905 1983)
Nobel 1970

1948, Raymond Alquist

. ,
,
: > > .
,
, : = >

Cannon,
: .
Raymond Alquist
(1914 - 1983)

,
. , ,
( 5 10-5)
, .
,
, .

(<2%).
3,4- (DOPA: DihydrOxyPhenylAlanine) -
. 1964
4 60 kDa.
, .

, ,

.
,
--, --p- (),

269

270

1. :
,

.

--p- ()

DOPA (-),
DOPA-,
5- ( , .
6). ,
6,
.

DOPA ,
--dopa- (carbidopa). carbidopa
Parkinson L-DOPA, Sinemet.
, , , , L-DOPA,
, DA,
. carbidopa,
, DOPA- ,
L-DOPA .
1

.

.

: ,

--dopa-
(carbidopa)

,
.
.

6.25 .
+ DA,
+, .
+ .

,
, ,
(vesicular monoamine transporter, VMAT).
, , Ca2+
, . ,
, :
.
H Reserpine 1952 Rauwolfia serpentina
(Indian snakeroot), Sarpagandha
, .
.
Robert Wallace Wilkins 1950.
1953 1954.
Reserpine ( ),
VMAT.

271

272

Reserpine ,
.

, ,
. ,
- .
290 kDa Cu2+, 4
.
. - , Cu2+
Cu2+.
(DDC) FLA 63,
Cu2+.
, Fusarium heterosporium,
.
.

,
.
, ,
, -.
- ,
30 kDa.

() -- (COMT). H ,
.

: ,

.

, .
,
.
( ) -
, .
s ,
, , , , .
, . (OCD).

-, (
), .
- ,
MAO-B Parkinson.

: -

: - - Parkinson

s ,
. ,
.

273

274

,
, .
.
, , , ,
. cheese effect
(.
, , ).

C, Axelrod 1957. ,
S - .

90%

10% COMT

6.26 . DA:
90% DA 10%
COMT. DOPAC, HVA 3-.

: ,

90% DA .
3,4- (DHPA), 3,4 (DOPAC) .
40% DOPAC
COMT. 60% (HVA). DOPAC
HVA .
, 10% DA,
COMT, DA 3- (3-),
HVA .

COMT

6.27 .
:
COMT. (DHPGA MHPGA)
DHPG MHPG DHMA VA.

, DA :
COMT,

275

276

6.27.
, (3,4
(DHPGA)

3--4-- (MHPG)) .
.

3--4- (MHPG), ,
(VMA),
.
COMT
, ,
.
,
,
.
Tolcapone COMT
Parkinson levodopa/carbidopa ,
aromatic L-amino acid decarboxylase (AADC).

. ,

,
, ,
(DA
NE uptake). ( 5-)
,
Na+ ,
Na+-K+-ATP ( Na+-K+).
. Na+
, DA . Cl-
, .
DA
12 , 60-85 kDa,

5-,
GABA.


, , ,
.

: ,

DA,
.

,
,
, .
,
,
.
1859
( Novocain).
1932,
,
.
1960, .
,

. crack

1980.
,

()

1960,

5-,
, DA.

5- ,


.

277

278

(10-100 g/gm),
(1000-3000 g/gm).

.


.

: ,

4:1.
, ,
.

6.28

.

(substantia nigra)
(ventral
tegmental area)
:


(caudate putamen)

.


(cortex)
( )

.

(locus ceruleus)

(,
, ).
(lateral tegmental
area)
.

:
(locus ceruleus)

(lateral ventral tegmental fields).

.
:
, ,
, .
.
.
,

279

280

.
: 1) , 2)
3) .
,
. ,
,
.

.
;
R. Nicoll et al,
( -
), ,
( -
). , -
,
,
.

. (
40.000
5000).
: (substantia
nigra) (ventral tegmental area).

(striatum)) .

(cortex) ( )
.

6.29 :
.

: ,

Ahlquist, 1948,
, .
( ) -,
(phentolamine)
.

: -
: -

1967, Lands - : 1
, 2
.
1974, Langer - : 1
2 , 1981, Starke
1 (prazosin) 2
(yohimbine).
, ,
1- (1, 1, 1D), 2 (2, 2B, 2C) - (1, 2, 3).

1 2,
(Langer, 1974),
(Starke, 1981), C (McGrath, 1982).

281

282

6
.

Morrow & Greese (1986)

1- , 1 1, ,
WB4101
1 1 ,
(pKD>9).
, Perez (1991)
1
. 1D. ,
100-1000 1
. , , :
D3213: 500 1
1, 50 1D,
5-- (5-methyl-urapidil), (oxymetazolin),
(+) (+niguldipine) SNAP5089: 100
1 1 1D,
RS17053: 50-60 1 1
1D,
11110: 30 1 1 1D,
7378, SKF105854 SKF104856: 50-100
1D 1 1.
.
,
mRNA .

.

1A, 1 1D :
C (PLC)
(3).
1A ,
, Ca2+-
, ,
1, 3
.
.

- 1 . 1-
7 ,
G.
, , (
1 ).
90 1D, 42 1, 25 1.

C, .
1
(161 ).
. (25 )
,
( )
. -
: (-COO-)

: ,

Asp113 (1) Asp125 (1) ,

(3+) , + Ser209 (3)
Ser207 (1) V
(-) , Phe290 (1) V

. 1 1
: Ala204 (V) Leu314 (VI) 1
Val185 Met293 1.
,
(Cys-Cys). - Cys
,
. ,
G. 27 (
233 254) 1
1 1
PLC, .

1-, (
),
.
,
1, 1, 1D
.
1-, .
, ,
, ()
.

283

284

xymetazoline: 1-

Phenylephrine: 1-

1- doxazolin prazosin
.
2 .
.
. 2-

: ,

2 ,
,
,
.
2-
, . 1 -
1950. ,
2- , ,
, .
2- .
2- ,
().

Clonidine: 2-

285

286

, REM,
.
, 2010,
ADHD (Attention deficit
hyperactivity disorder) .

2-

(prefrontal
cortex PFC).

(yohimbine)
Pausinystalia yohimbe (Yohimbe), . 2-,
,
.
. ,
, ,
. ,

, .
2-
, 1-20% 55
.

4.19
Pausinystalia yohimbe,
2-,
,
, .

: ,

- 1, 2 3, Gs
, ,
cAMP. 1- 1/ ,
( ), 2/
.

(atenolol) 1 blocker 1976

Tenormin, . ,

.

287

288

(metoprolol) 1 blocker
, ,
.

Atenolol: 1-blocker

Metoprololl: 1-blocker

2 , ,
. -

.
(salmeterol) 2-
(chronic obstructive
pulmonary disease, COPD).
. GlaxoSmithKline
1980 1990 Serevent.
(salbutamol) 2-
. 2 1968 Ventolin.
.
( 20 min) .

Adem A. and Karlson E., Muscarinic receptor subtype selective toxins,

Life Sci.,1997, 60(13-14), 1069-1076
Alabaster VA., Discovery and development of selective M3 antagonists for clinical use,
Life Sci.,1997, 60(13-14), 1053-1060
Ashkenazi A. and Peralta EG., Muscarinic acetylcholine receptors, in Handbook of
receptors and channels, Ed. by Stephen Peroutka, CRC Press, 1994
Avery EE., Baker LD. and Astana S., Potential role of muscarinic agonists in Alzheimers
disease, Drugs Aging, 1997, 11(6), 450-459

: ,

Barnes PJ., Haddad EB. and Rousell J., Regulation of muscarinic M2 receptors, Life
Sci.,1997, 60(13-14), 1015-1021
Birdsall NJ. et al, Selective allosteric enhancement of the binding and actions of
acetylcholine and muscarinic receptor subtypes, Life Sci.,1997, 60(13-14), 10471052
Brann MR., et al, Studies of the pharmacology, localization, and stucture of muscarinic
acetylcholine receptors, Ann. N.Y. Acad. Sci., 1993, 707, 225-236
Brown DA. et al, Muscarinic mechanisms in nerve cells, Life Sci.,1997, 60(13-14), 11371140
Brown JH. et al, Pathways and roadblocks in muscarinic receptor-mediated growth
regulation, Life Sci.,1997, 60(13-14), 1077-1084
Eglen RM., Hegde SS. and Watson N., Muscarinic receptor subtypes and smooth muscle
function, Pharmacol. Rev., 1996, 48(4), 531-565
Eglen RM. and Watson N., Selective muscarinic receptor agonists and antagonists,
Pharmacol. Toxicol., 1996, 78(2), 59-68
Felder CC., Muscarinic acetylcholine receptors: signal transduction trough multiple
effectors, FASEB J., 1995, 9(8), 619-625
Fisher A. et al, M1 agonists for the treatment of Alzheimers disease. Novel properties and
clinical update, Ann. N.Y. Academ. Sci., 1996, 777, 189-196
Jerusalinsky D. and Harvey A.L., Toxins from mamba venoms: small proteins with
selectivities for different subtypes of muscarinic acetylcholine receptors, Trends
Pharmacol. Sci., 1994, 15, 424-430
Hosey MM. et al, The role of G protein coupled receptor kinases in the regulation of
muscarinic cholinergic receptors, Prog. Brain Res., 1996, 109, 169-179
Klein J., Lindmar R. and Loffelholz K., Muscarinic activation of phosphatidyllcholine
hydrolysis, Prog. Brain Res., 1996, 109, 201-208
Lester HA., Activation of ion channels by acetylcholine: two contrasting transduction
pathways, Harvey Lect., 1995, 91, 79-98
Levey AI., Muscarinic acetylcholine receptor expression in memory circuits: implications
for treatment of Alzheimer disease, Proc. Natl. Acad. Sci. (USA), 1996, 93(24),
13541-13546
Loffelholz K., Muscarinic receptors and cell signalling, Prog. Brain Res., 1996, 109, 191194
Marchi M. et al, Presynaptic interactions between acetylcholine and glycine in the human
brain, Prog. Brain Res., 1996, 109, 225-229
Nahorski SR., Tobin AB. and Willars GB., Muscarinic M3 receptor coupling and
regulation, Life Sci.,1997, 60(13-14), 1039-1045
Nathanson NM., Regulation of muscarinic acetylcholine receptor expression and function,
Prog. Brain Res., 1996, 109, 165-168
Reever CM., Ferrari-DiLeo G. and Flynn DD., The M5 (m5) receptor subtype? fact or
fiction? Life Sci.,1997, 60(13-14), 1105-1112
Russell RW., Continuing the search for cholinergic factors in cognitive dysfunction, Life
Sci.,1996, 58(22), 1965-1970
Segal M. and Auerbach JM., Muscarinic receptors involved in hippocampal plasticity, Life
Sci.,1997, 60(13-14), 1085-1091
Tucek S. and Proska J., Allosteric modulation of muscarinic acetylcholine receptors,
Trends Pharmacol. Sci., 1995, 16(6), 205-212
Wess J., Molecular biology of muscarinic acetylcholine receptors, Crit. Rev. Neurobiol.,
1996, 10(1) 69-99

289

290

Wess J. et al, Structural basis of receptor/G protein coupling selectivity studied with
muscarinic receptors as model systems, Life Sci.,1997, 60(13-14), 1007-1014
Wess J. et al, Molecular aspects of muscarinic receptor assembly and function, Prog. Brain
Res., 1996, 109, 153-162

Albuquerque EX., et al, Nicotinic acetylcholine receptors on hippocampal neurons:
distribution on the neuronal surface and modulation of receptor activity, J. Recept.
Signal Transduct. Res., 1997, 17(1-3), 243-266
Arias HR., Topology of ligand binding sites on the nicotinic acetylcholine receptor, Brain
Res. Rev., 1997, 25(2), 133-191
Barrantes FJ., The acetylcholine receptor ligand-gated channel as a molecular target of
disease and therapeutic agents, Neurochem. Res., 1997, 22(4), 391-400
Birtwistle J. and Hall K., Does nicotine have beneficial effects in the treatment of certain
diseases? Br. J. Nurs., 1996, 5(19), 1195-1202
Boyd RT., The molecular biology of neuronal nicotinic acetylcholine receptors, Crit. Rev.
Toxicol., 1997, 27(3), 299-318
Changeux JP. et al, Nicotinic receptors and brain plasticity, Cold Spring Harb. Symp.
Quant. Biol., 1996, 61, 343-362
Clarke PB., Nicotinic receptors in mammalian brain: localization and relation to
cholinergic innervation, Prog. Brain Res., 1993, 98, 77-83
Colquhoun LM. and Patrick JW., Pharmacology of neuronal nicotinic acetylcholine
receptor subtypes, Adv. Pharmacol., 1997, 39, 191-220
Dani JA. and Heinemann S., Molecular and cellular aspects of nicotine abuse, Neuron,
1996, 16(5), 905-908
Froehner SC., Regulation of ion channel distribution at synapses, Ann. Rev. Neurosci.,
1993, 16, 347-368
Galzi JL. and Changeux JP., Neuronal nicotinic receptors: molecular organization and
regulations, Neuropharmacology, 1995, 34(6), 563-582
Gillin JC. et al, Cholinergic receptor subtypes and REM sleep in animals and normal
controls, Prog. Brain Res., 1993, 98, 379-387
Gotti C., Fornasari D. and Clementi F., Human neuronal nicotinic receptors, Prog.
Neurobiol., 1997, 53(2), 199-237
Hucho F., Tsetlin VI. and Machold J., The emerging three-dimensional structure of a
receptor. The nicotinic acetylcholine receptor, Eur. J. Biochem., 1996, 239(3), 539557
Imoto K., Ion channels: molecular basis of ion selectivity, FEBS Lett., 1993, 325(1-2),
100-103
Karlin A. and Akabas MH., Toward a structural basis for the function of nicotinic
acetylcholine receptors and their cousins, Neuron, 1995, 15(6), 1231-1244
Lindstrom J., Nicotinic acetylcholine receptors in health and disease, Mol. Neurobiol.,
1997, 15(2), 193-222
Lindstrom J. et al, Structure and function of neuronal nicotinic acetylcholine receptors,
Prog. Brain Res., 1996, 109, 125-137
Lena C. and Changeux JP., Allosteric modulations of the nicotinic acetylcholine receptor,
Trends Neurosci., 1993, 16(5), 181-186
Maelicke A., Nicotinic receptors of the vertebrate CNS: introductory remarks, Prog. Brain
Res., 1996, 109, 107-110

: ,

McGehee DS. and Role LW., Physiological diversity of nicotinic acetylcholine receptors
expressed by vertebrate neurons, Ann. Rev. Physiol., 1995, 57, 521-546
Newhouse PA., Potter A. and Levin ED., Nicotinic system involvement in Alzheimers
and Parkinsons diseases. Implications for therapeutics, Drugs Aging, 1997, 11(3),
206-228
Ortells MO. and Lunt GG., Evolutionary history of the ligand-gated ion-channel
superfamily of receptors, Trends Neurosci.,1995, 18(3), 121-127
Role LW. and Berg DK., Nicotinic receptors in the development and modulation of CNS
synapses, Neuron, 1996, 16(6), 1077-1085
Sargent PB., The diversity of neuronal nicotinic acetylcholine receptors, Ann. Rev.
Neurosci., 1993, 16, 403-443
Swope SL., Qu Z. and Huganir RL, Phosphorylation of the nicotinic acetylcholine receptor
by protein tyrosine kinases, Ann. N.Y. Acad. Sci., 1995, 757, 197-214
Vidal C., Nicotinic receptors in the brain. Molecular biology, function and therapeutics,
Mol. Chem. Neuropathol., 1996, 28(1-3), 3-11
Wonnacott S., Presynaptic nicotinic ACh receptors, Trends Neurosci., 1997, 20(2), 92-98

ifa E. and Fillion G., 5-hydroxytryptamine receptors, Pharmacol. Rev., 1992, 44, 401458.
Baxter G. et al, 5-HT2 receptor subtypes: a family re-united? TiPS, 1995,16, 105-109
Blier P., Bergeron R. and de Montigny C., Selective activation of postsynaptic 5-HT1A
receptors induces rapid antidepressant response, Neuropsychopharmacology, 1997,
16(5), 333-338
Boess FJ, and Martin IL., Molecular biology of 5-HT receptors, Neuropharmacology,
1994, 33, 275-317
Boess FJ. et al, Ultrastructure of the 5-hydroxytryptamine3 receptor, J. Neurochem., 1995,
64, 1401-1405
Buhot M.C, Serotonin receptors in cognitive behaviors, Curr. Opin. Neurobiol., 1997, 7(2),
243-254
Delgado PL., and Moreno FA., Hallucinogens, serotonin and obsessive-compulsive
disorder, J. Psychoactive Drugs, 1998, 30, 359-366
Engen R. et al, Central 5-HT4 receptors, TiPS, 1995,16, 391-397
Fanburg B.L. and Lee S.L., A new role for an old molecule: serotonin as a mitogen, Am. J.
Physiol., 1997, 272(5 Pt1): L795-L806
Fozard JR., and Kalkman HO., 5-Hydroxytryptamine and the initiation of migraine: new
perspectives, Naunyn-Schmiedebergs Arch. Pharmacol.,1994, 350, 225-9
Gilman P.K., The serotonin syndrome and its treatment, J. Psychopharmacol., 1999, 13,
100-9
Gthert M., et al, Genetic variation in human 5-HT receptors: potential pathogenetic and
pharmacological role, Ann. N.Y. Acad. Sci., 1998, 861, 26-30
Grant K.A., The role of 5-HT3 receptors in drug dependence, Drug and Alcool
Metabol.,1995, 38, 155-171
Hagan RM., Kilpatrick GJ., and Tyers MB., Interactions between 5-HT3 receptors and
cerebral dopamine function: implications for the treatment of schizophrenia and
psychoactive substance abuse, Psychopharmacology, 1993, 112, S68-75
Hartig P. et al, Alignment of receptor nomenclature with the human genome classification
of 5-HT1B and 5-HT1D receptor subtypes, TiPS, 1996, 17, 103-105

291

292

Hindle AT., Recent developments in the physiology and pharmacology of 5hydroxytryptamine, Br. J. Anaesth., 1994, 73, 395-407
oyer D. et al, International union of pharmacology classification of receptors for 5hydroxytryptamine (serotonin), Pharmacol. Rev., 1994, 46, 157-203
Hoyer D, et al, 5-Ht receptor classification and nomenclature: towards a harmonization
with the human genome, Neuropharmacology, 1997, 36(4-5), 419-428
Jackson . and Yakel J., The 5-HT3 receptor channel, Annu. Rev. Physiol., 1995, 57, 44768
Johnson K.W., et al, Serotonin in migraine: theories, animal models and emerging
therapies, Prog. Drug Res., 1998, 51, 219-44
Jolas T. et al, Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects 5-HT1A
receptor agonists and in their inhibitory effects on the firing of serotonergic neurons
in the rat? J. Pharmacol. Exper. Ther., 1995, 272, 920-929
Kirk E.E. et al, Serotonergic receptors as targets for pharmacology, J. Neurosci. Nurs.,
1997, 29(3), 191-197
Kroeze W.K, and Roth B.L., The molecular biology of serotonin receptors: therapeutic
implications for the interface of mood and psychosis, Biol. Psychiatry, 1998, 44,
1128-42
Martin GR, and Humphrey PP., Receptors for 5-Hydroxytryptamine: current perspectives
on classification and nomenclature, Neuropharmacology, 1994, 33, 261-73
Martin GR., et al, The structure and signaling properties of 5-HT receptors: an endless
diversity? TiPS, 1998, 19, 2-4
Morin L.P., Serotonin and the regulation of mammalian circadian rhythmicity, Ann. Med.,
1999, 31, 12-33
Olmo E. Et al, Ontogenetic development of 5-HT1D receptors in human brain: an
autoradiographic study, Eur. J. Neurosci.,1996, 8, 53-60
Parker R. et al, Allosteric modulation of 5-HT3 receptors: focus on alcohols and
anaesthetic agents, TiPS, 1996, 17, 95-99
Pauwels PJ., 5-HT1B/1D receptor antagonists, Gen. Pharmacol., 1997, 29(3), 293-303
Peroutka SJ, and Howell TA., The molecular of G protein-coupled receptors: focus on 5Hydroxytryptamine receptors, Neuropharmacology,1994, 33, 319-24
Roila F. and Del Favero A., Antiemetics revisited, Cuur. Opin. Oncol., 1997, 9(4), 321326
Seguin L. et al, The endogenous cerebral tetrapeptide 5-HT-moduline reduces in vivo the
functional activity of central 5-HT1B receptors in the rat, Neurosci. Res., 1997, 27,
277-280
Uphouse L., Multiple serotonin receptors: too many, not enough, or just the right number?
Neurosci. Biobehav. Rev., 1997, 21, 679-698
Van den Wyngaert I., et al, Cloning and expression of a human serotonin 5-HT4 receptor
cDNA, J. Neurochem., 1997, 69(5), 1810-1819
Whitaker-Azmitia PM., et al, Serotonin as a developmental signal, Behav. Brain Res.,
1996, 73, 19-29
Arnsten AF., Catecholamine regulation of the prefrontal cortex, J. Psychopharmacol.,
1997, 11, 151-162
Bremner JD., et al, Noradrenergic mechanisms in stress and anxiety: II. Clinical studies,
Synapse, 1996, 23, 39-51
Bylund DB., Pharmacological characteristics of alpha2-adrenergic receptor subtypes, ANN.
N.Y. Acad. Sci., 1995, 763, 1-7

: ,

Cooper JR., Bloom FE., Roth RH., ,

, 1996, ( 9: , .163207)
Cotecchia S., et al, Molecular mechanisms underlying the activation and regulation of the
alpha1B -adrenergic receptor, Biochem. Soc. Trans., 1996, 24, 959-963
Cotecchia S., et al, Signalling and regulation of the alpha1B-adrenergic receptor, Biochem.
Soc. Trans., 1995, 23, 121-125
Day H.E.W., Campeau S., Watson S.J. and Akil H., Distribution of 1a, 1b, and 1dadrenergic receptor mRNA in the rat brain and spinal cord, J. Chemical
Neuroanatomy, 1997, 13, 115-139
De Ponti F., Pharmacological criteria for the detection of beta3-adrenoceptors, Trends
Pharmacol. Sci., 1997, 18, 52-53
Dinan TG., Noradrenergic and serotonergic abnormalities in depression: stress-induced
dysfunction? J. Clin. Psychiatry, 1996, 57 (Suppl4), 14-18
Frazer A., Pharmacology of antidepressants, J. Clin. Psychopharmacol., 1997, 17(2), 2S18S
Garcia-Sainz JA., 1-adrenergic action: receptor subtypes, signal transduction and
regulation, Cell Signal., 1993, 5, 539-545
Garcia-Sainz JA., Adrenaline and its receptors: one hundred years of research, Arch. Med.
Res., 1995, 26, 205-212
Garcia-Sainz JA., Vazquez-Prado J., and del Carmen Medina L., 1-adrenoceptors:
function and phosphorylation, Eur. J. Pharmacology, 2000, 389, 1-12
Goldstein DS., Catecholamine receptors and signal transduction. Overview, Adv.
Pharmacol., 1998, 42, 379-390
Grace AA., Gerfen CR., Aston-Jones G., Catecholamines in the central nervous system.
Overview, Adv. Pharmacol., 1998, 42, 655-670
Graham RM., et al, Characterization of 1-adrenergic receptor subtypes, Pharmacol.
Commun., 1995, 6, 15-22
Graham RM., et al, alpha1-adrenergic receptor subtypes. Molecular structure, function, and
signaling, Circ. Res., 1996, 78, 737-749
Grunberg SM., Future of the management of emesis, Support Care Cancer, 1994, 2, 301303
Guarino RD., Perez DM., Piascik MT., Recent advances in the molecular pharmacology of
the alpha1 -adrenergic receptors, Cell Signal, 1996, 8, 323-333
Hein L., Kobilka BK., Adrenergic receptor signal transduction and regulation,
Neuropharmacology, 1995, 34, 357-366
Hieble JP., and Bond RA., New directions in adrenoceptor pharmacology, Trends
Pharmacol. Sci., 1994, 397-399
Hieble JP., Bondinell WE., Ruffolo RR. Jr, Alpha- and beta-adrenoceptors: from the gene
to the clinic. 1. Molecular biology and adrenoceptor subclassification, J. Med.
Chem., 1995, 38, 3415-3444
Hieble JP., et al, International Union of Pharmacology. X. Recommendation for
nomenclature of alpha1-adrenoceptors: consensus update, Pharmacol. Rev., 1995, 47,
267-270
Hieble JP., Ruffolo RR Jr., Subclassification and nomenclature of alpha 1- and alpha 2adrenoceptors, Prog. Drug Res., 1996, 47, 81-130
Kamibayashi T., Harasawa K., Maze M., Alpha2- adrenergic agonists, Can. J. Anaesth.,
1997, 44(5 Pt2), R13-R22
Leon M., Catecholaminergic contributions to early learning, Adv. Pharmacol., 1998, 42,
961-964

293

294

Leonard BE., Noradrenaline in basic models of depression, Eur. Neuropsychopharmacol.

1997, 7 (Suppl1), S11-S16
Leonard BE., The role of noradrenaline in depression: a review, J. Psychopharmacol.,
1997, 11(4Suppl), S39-S47
Lipworth BJ., Clinical pharmacology of beta3-adrenoceptors, Br. J. Clin. Pharmacol.,1996,
42, 291-300
McEwen BS., Sapolsky RM., Stress and cognitive function, Curr. Opin. Neurobiol., 1995,
5, 205-216
McGaugh JL., Cahill L., Roozendaal B., Involvement of the amygdala in memory storage:
interaction with other brain systems, Proc. Natl. Acad. Sci. (USA), 1996, 93, 1350813514
McKinnon AC., Spedding M., Brown CM., 2-adrenoceptors: more subtypes but fewer
functional differences, Trends Pharmacol. Sci., 1994, 15, 119-123
Mersmann HJ., Overview of the effects of beta-adrenergic receptor agonists on animal
growth including mechanisms of action, J. Anim. Sci., 1998, 76, 160-172
Mersmann HJ., Species variation in mechanisms for modulation of growth by betaadrenergic receptors, J. Nutr., 1995, 125 (Suppl6), 1777S-1782S
Michel MC., Kenny B., Schwinn DA., Classification of alpha1-adrenoceptor subtypes,
Naunyn Schmiedebergs Arch. Pharmacol., 1995, 352, 1-10
Milligan G. and Bond RA., Inverse agonism and the regulation of receptor number, Trends
Pharmacol. Sci., 1997, 18, 468-474
Milligan G., Svoboda P., Brown CM., Why are there so many adrenoceptor subtypes?
Biochem. Pharmacol., 1994, 48, 1059-1071
Minneman K.P., and Esbenshade T.A., 1-adrenergic receptor subtypes, Annu. Rev.
Pharmacol. Toxicol., 1994, 34, 117-133
Nicholas AP., Hokfelt T., Pieribone VA., The distribution and significance of CNS
adrenoceptors examined with in situ hybridization, Trends Pharmacol. Sci., 1996,
17, 245-255
Pepperl D.J., and Regan J.W., Adrenergic receptors, in Handbook of receptors and
channels, Ed. by Stephen Peroutka, CRC Press, 1994
Potter PC., Genetic abnormalities of the human beta2-adrenergic receptor, Clin. Exp.
Allergy, 1995, 25, 596-598
Potter WZ., Adrenoceptors and serotonin receptor function: relevance to antidepressant
mechanisms of action, J. Clin. Psychiatry, 1996, 57 (Suppl4), 4-8
Rohrer DK. and Kobilka BK., G protein-coupled receptors: functional and mechanistic
insights through altered gene expression, Physiol. Rev., 1998, 78, 35-52
Ruffolo RR. Jr, Bondinell W., Hieble JP., Alpha- and beta-adrenoceptors: from the gene to
the clinic. 2. Structure-activity relationships and therapeutic applications, J. Med.
Chem., 1995, 38, 3681-3716
Sambunaris A., et al, Development of new antidepressants, J. Clin. Psychiatry, 1997, 58
(Suppl6), 40-53
Sirvi J., and MacDonald E., Central 1-adrenoreceptors: Their role in the modulation of
attention and memory formation, Pharmacology & Therapeutics, 1999, 83, 49-65
Smiley RM., Finster M., Do receptors get pregnant too? Adrenergic receptor alterations in
human pregnancy, J. Matern. Fetal Med., 1996, 5, 106-114
Stanford SC., Central noradrenergic neurons and stress, Pharmacol. Ther., 1995, 68, 297242
Strosberg AD., Association of beta3-adrenoceptor polymorphism with obesity and
diabetes: current status, Trends Pharmacol. Sci., 1997, 18, 449-454

: ,

Strosberg AD., Function and regulation of the beta3-adrenoceptor, Trends Pharmacol. Sci.,
1996, 17, 373-381
Strosberg AD., Structural and functional diversity of beta-adrenergic receptors, Ann. N.Y.
Acad. Sci., 1995, 757, 253-260
Strosberg AD., Structure and function of the beta3-adrenergicreceptor, Annu. Rev.
Pharmacol. Toxicol., 1997, 37, 421-450
Strosberg AD., Structure, function, and regulation of the three beta-adrenergic receptors,
Obes. Res., 1995, 3 (Suppl4), 501S-505S
Tobin AB., Phosphorylation of phospholipase C-coupled receptors, Pharmacol. Ther.,
1997, 75, 135-151

295

296